These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 378472)

  • 1. [Biological activities of somatostatin analogs (author's transl)].
    Kokubu T; Sawano S
    Horumon To Rinsho; 1979 May; 27(5):473-82. PubMed ID: 378472
    [No Abstract]   [Full Text] [Related]  

  • 2. Synthesis and biological activity of highly potent heptapeptide analogs of somatostatin with C-terminal modifications.
    Janecka A; Zubrzycka M
    Endocr Regul; 2001 Jun; 35(2):75-9. PubMed ID: 11563935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The use of somatostatin analogs in the treatment of patients with digestive system diseases].
    Frol'kis AV
    Ter Arkh; 1999; 71(2):83-5. PubMed ID: 10222565
    [No Abstract]   [Full Text] [Related]  

  • 4. [In vivo assay of antisomatotropic activity of somatostatin and two of its analogs].
    Franchimont P; Ghys A; Brison J; Haze-Hagelstein MT; Detournay JM; Dremier C; Scarso A; Demoulin A; Dirkx J
    C R Seances Soc Biol Fil; 1977; 171(3):673-8. PubMed ID: 144010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro testing of new somatostatin analogs on pituitary tumor cells.
    Zatelli MC; Ambrosio MR; Bondanelli M; degli Uberti EC
    Mol Cell Endocrinol; 2008 May; 286(1-2):187-91. PubMed ID: 18243520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A tetradecapeptide somatostatin dicarba-analog: Synthesis, structural impact and biological activity.
    Martín-Gago P; Ramón R; Aragón E; Fernández-Carneado J; Martin-Malpartida P; Verdaguer X; López-Ruiz P; Colás B; Cortes MA; Ponsati B; Macias MJ; Riera A
    Bioorg Med Chem Lett; 2014 Jan; 24(1):103-7. PubMed ID: 24342240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of somatostatin analogs in the management of prostate cancer.
    Sinisi AA; Rossi V; Prezioso D; Notaro A; Bellastella G; Panza N; Bellastella A; Pasquali D
    J Endocrinol Invest; 2003; 26(8 Suppl):120-4. PubMed ID: 15233227
    [No Abstract]   [Full Text] [Related]  

  • 8. Somatostatin analogs: does pharmacology impact antitumor efficacy?
    Chalabi M; Duluc C; Caron P; Vezzosi D; Guillermet-Guibert J; Pyronnet S; Bousquet C
    Trends Endocrinol Metab; 2014 Mar; 25(3):115-27. PubMed ID: 24405892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity relationship studies of novel somatostatin analogs with antitumor activity.
    Kéri G; Mezô I; Vadász Z; Horváth A; Idei M; Vántus T; Balogh A; Bökönyi G; Bajor T; Teplán I
    Pept Res; 1993; 6(5):281-8. PubMed ID: 7903057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effects of somatostatin.
    Pyronnet S; Bousquet C; Najib S; Azar R; Laklai H; Susini C
    Mol Cell Endocrinol; 2008 May; 286(1-2):230-7. PubMed ID: 18359151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel heptapeptide somatostatin analog displays anti-tumor activity independent of effects on growth hormone secretion.
    Murphy WA; Taylor JE; Moreau JP; Coy DH
    Pept Res; 1989; 2(1):128-32. PubMed ID: 2577697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Common structural features for cytoprotection activities of somatostatin, antamanide and related peptides.
    Kessler H; Gehrke M; Haupt A; Klein M; Müller A; Wagner K
    Klin Wochenschr; 1986; 64 Suppl 7():74-8. PubMed ID: 2882054
    [No Abstract]   [Full Text] [Related]  

  • 13. Extended retro-inverso analogs of somatostatin.
    Pallai P; Struthers S; Goodman M; Rivier J; Vale W
    Biopolymers; 1983 Dec; 22(12):2523-38. PubMed ID: 6141815
    [No Abstract]   [Full Text] [Related]  

  • 14. Triglyceride lowering effect of somatostatin and its analogs.
    Schusdziarra V; Brown M; Rivier J; Vale W; Dobbs R; Raskin P; Unger RH
    FEBS Lett; 1977 Jul; 79(1):133-4. PubMed ID: 891920
    [No Abstract]   [Full Text] [Related]  

  • 15. Analogs of somatostatin. Part B. In vivo activities: prolongation of action with protamine zinc.
    Brazeau P; Martin JB
    Curr Top Mol Endocrinol; 1976; 3():379-86. PubMed ID: 1052676
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular aspects of cytoprotection by modified somatostatins.
    Ziegler K; Frimmer M
    Klin Wochenschr; 1986; 64 Suppl 7():87-9. PubMed ID: 2882056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin analogs for the treatment of neuroendocrine tumors.
    Culler MD; Oberg K; Arnold R; Krenning EP; Sevilla I; Díaz JA
    Cancer Metastasis Rev; 2011 Mar; 30 Suppl 1():9-17. PubMed ID: 21369878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of somatostatin analogs in the control of tumor growth.
    Lamberts SW; Reubi JC; Krenning EP
    Semin Oncol; 1994 Oct; 21(5 Suppl 13):61-4. PubMed ID: 7992085
    [No Abstract]   [Full Text] [Related]  

  • 19. Feeding responses to central administration of several somatostatin analogs in chicks.
    Tachibana T; Cline MA; Khan MS; Ueda H; Hiramatsu K
    Comp Biochem Physiol A Mol Integr Physiol; 2011 Jan; 158(1):47-51. PubMed ID: 20826222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors.
    Hasskarl J; Kaufmann M; Schmid HA
    Future Oncol; 2011 Jul; 7(7):895-913. PubMed ID: 21732759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.